Ogawa O, Habuchi T, Kakehi Y, Koshiba M, Sugiyama T, Yoshida O
Department of Urology, Faculty of Medicine, Kyoto University, Japan.
Cancer Res. 1992 Apr 1;52(7):1881-5.
Recent studies have demonstrated that allelic losses at chromosome 17p are associated with the genesis of a wide variety of human cancers. In order to assess whether the rearrangement of chromosome 17p was responsible for the genesis of renal cell carcinoma (RCC), we used restriction fragment length polymorphism analysis of chromosome 17p. We studied 48 RCCs, including 6 metastatic RCCs, from 43 patients with 5 polymorphic probes to loci within or near the p53 gene. Allelic losses at chromosome 17p were detected in only 6 of the 36 informative cases (17%), and no definitive correlation was demonstrated between allelic losses at 17p and the tumor stages. The 6 RCCs with allelic losses at 17p were histopathologically classified as a clear cell type in one, a mixed cell type in one, and granular cell types in the other four cases. Allelic losses at 17p in the clear cell type of RCC were infrequent (6%, 1 of 18), and were not detected even in the metastatic tumor from a highly advanced case. This finding suggests that allelic losses at 17p could be random genetic rearrangements in the case of the clear cell type of RCC. On the other hand, allelic losses at 17p in the granular cell type of RCC were demonstrated with a significantly higher frequency (44%, 4 of 9). We previously reported that allelic losses at 3p were specific to the clear cell type of RCC (Ogawa et al., Cancer Res., 51:949-953, 1991). Examination of the association of allelic losses at 17p with those at 3p revealed that none of 5 informative RCCs with allelic losses at 17p showed allelic losses at 3p. Conversely, 17 of 25 informative RCCs with retention of 17p alleles lost alleles at 3p. Thus, an inverse relationship was demonstrated with statistical significance (P less than 0.01). These data suggest that the types of rearrangement on chromosome 17p and/or chromosome 3p can differentiate between the histopathological subtypes of RCC.
最近的研究表明,17号染色体短臂上等位基因的缺失与多种人类癌症的发生有关。为了评估17号染色体短臂的重排是否与肾细胞癌(RCC)的发生有关,我们采用了17号染色体短臂的限制性片段长度多态性分析。我们研究了来自43例患者的48个肾细胞癌,包括6个转移性肾细胞癌,使用5个多态性探针检测p53基因内部或附近的位点。在36例信息充分的病例中,仅6例(17%)检测到17号染色体短臂上等位基因的缺失,并且未显示17号染色体短臂上等位基因的缺失与肿瘤分期之间存在明确的相关性。17号染色体短臂上等位基因缺失的6个肾细胞癌在组织病理学上,1例为透明细胞型,1例为混合细胞型,另外4例为颗粒细胞型。透明细胞型肾细胞癌中17号染色体短臂上等位基因的缺失很少见(6%,18例中的1例),甚至在1例晚期转移瘤中也未检测到。这一发现表明,对于透明细胞型肾细胞癌,17号染色体短臂上等位基因的缺失可能是随机的基因重排。另一方面,颗粒细胞型肾细胞癌中17号染色体短臂上等位基因的缺失频率显著更高(44%,9例中的4例)。我们之前报道过,3号染色体短臂上等位基因的缺失是透明细胞型肾细胞癌所特有的(小川等人,《癌症研究》,51:949 - 953,1991)。对17号染色体短臂上等位基因缺失与3号染色体短臂上等位基因缺失之间关联的研究发现,17号染色体短臂上等位基因缺失的5例信息充分的肾细胞癌中,没有1例在3号染色体短臂上显示等位基因缺失。相反,25例17号染色体短臂等位基因保留的信息充分的肾细胞癌中有17例在3号染色体短臂上丢失了等位基因。因此,两者呈现出具有统计学意义的负相关关系(P小于0.01)。这些数据表明,17号染色体短臂和/或3号染色体短臂上的重排类型可以区分肾细胞癌的组织病理学亚型。